AbbVie Shareholders Have a Lot to Look Forward To With Allergan – The Motley Fool

AbbVie's (NYSE:ABBV) third-quarter earnings call reminded investors about the transformative potential of the Allergan acquisition for the pharma giant. Management reiterated that they continue to expect the deal to close by the end of the first quarter of 2020. This is promising for investors, as the combined entity will allow AbbVie to gain a more diversified foothold in faster-growing therapeutic areas such as Botox and neuroscience while expanding its immunology portfolio with the addition of Allergan's Linzess and Viberzi.

AbbVie CEO Richard Gonzalez said on the earnings call that "the Allergan transaction will make us even stronger and more diversified." Let's see why.

Photo Credit: Getty Images

The new AbbVie will have a strong market leadership position in a number of therapeutic areas. AbbVie would be No. 1 in immunology, supported by its flagship arthritis treatment, Humira, but investors are also excited about potential approvals following results of ongoing Phase 3 clinical trials of Skyrizi in psoriasis and Upadacitinib in rheumatoid arthritis before the end of 2020. Not surprisingly, AbbVie will also have a market leadership position in medical aesthetics, with a product suite covering Botox, the CoolSculpting fat removal system, and Juvederm dermal fillers, which are used to help conceal wrinkles. Medical aesthetics is still a rapidly growing market, especially internationally. Management cited a Markets and Markets Medical Aesthetics report from September 2018 that cited the aesthetics addressable market being $12B at the time and "growing."

Investors should be encouraged by Gonzalez's comments on the call that, "Based on the uniqueness of this particular molecule, we have come to the conclusion that it would be extremely difficult to create a biosimilar version of Botox, and I would tell you, we looked at this very extensively with a lot of outside expertise and we feel very confident that that's the case." This should create a steady stream of earnings and cash flow to AbbVie to help support other therapeutic areas without the worry of generic competition.

The scale and synergies of the acquisition are another bright spot for investors in a world where size matters more than ever to fend off competition.

Let's start with scale. Using full-year 2018 financials, adding AbbVie and Allergan gives us an entity that would have trailed only Johnson & Johnson, Roche, and Pfizer in revenue, lagging only the first two in operating cash flow. With the company's new scale, management believes it can achieve high-single-digit revenue growth.

With respect to the synergies, management expects the combined entity to lower costs and increase returns. Total savings are expected to top $2 billion over a three-plus-year period: 50% from R&D efficiency; 40% from selling, general, and administrative expenses as the footprint of the combined organization becomes leaner; and 10% from greater manufacturing efficiency. Those savings should show up quickly: Earnings per share are expected to get a 10% boost in year one and eventually top 20%. This will help support the increase of an already generous 5%-plus dividend yield, coupled with the promise of further shareholder-friendly actions as the company reduces its debt load. Gonzalez said that "combined, we will generate significant earnings and cash flow to enhance our innovative R&D platform support a strong and growing dividend and rapidly pay down debt."

Year to date, AbbVie's stock price has been more or less flat, lagging the S&P 500. As a result, it's sporting a forward price-to-earnings multiple of roughly 10 times consensus estimates. That's not a steep price for an attractive dividend yield coupled with the prospect of accelerating revenue and earnings growth.

As closure of the acquisition draws near, any negative investor sentiment should begin to abate, allowing for the prospects of multiple expansion. Gonzalez said on the call, "Our model is more conservative than what the Allergan current performance is and certainly more conservative than their longer-range forecast, but it still does project growth for Botox going forward." Thus, this multiple expansion should be led by reduced fears around competition, realized cost synergies, and potential for increased earnings guidance.

More here:
AbbVie Shareholders Have a Lot to Look Forward To With Allergan - The Motley Fool

Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug…

BOSTON--(BUSINESS WIRE)--Immunitas Therapeutics (Immunitas), a single cell genomics-based drug discovery company founded by Longwood Fund, today announced a $39 million Series A financing led by Leaps by Bayer and Novartis Venture Fund and joined by additional investors including Evotec, M Ventures, Alexandria Venture Investments, and other institutional investors. The company plans to use this funding to advance its first programs, monoclonal antibody therapeutics with single agent activity in preclinical models of oncology, to clinical studies.

Underlying the companys programs is the unique drug development platform crafted by the Immunitas team along with Aviv Regev (Professor of Biology and Core Member of the Broad Institute and Investigator at the Howard Hughes Medical Institute) that dissects the microenvironment of human tumors using single cell genomics-based approaches to identify novel immune targets. The Immunitas platform has generated fully humanized antibodies that act on these targets, advancing to human efficacy studies driven by specific clinical biomarkers, and a breadth of promising druggable cancer targets.

The scientific founders of Immunitas are pioneers in studying the immunobiology of human tumors, including the use of single cell genomics-based techniques and antibody-development techniques:

Single cell genomic sequencing has tremendous promise to help unravel the interactions between immune cells and cancer cells in tumors to advance cancer drug development but focusing it appropriately to discover meaningful new targets based on human biology has been challenging, said Dr. Wucherpfennig. The Immunitas platform is designed to reveal novel and important adaptive and innate immune interactions with tumor cells, which may open up new possibilities in cancer therapy. My scientific co-founders and I look forward to continuing to work with the Immunitas team as they advance this powerful science.

Our scientific founders are pioneers in the field of single cell sequencing and analysis. They have extensive expertise in deep computational biology, which has enabled us to discover novel therapeutic targets directly from human immunology, said Lea Hachigian, Ph.D., co-founder, director and President of Immunitas Therapeutics. The data from this platform have also provided us with biomarkers for patient selection, which has potential to accelerate our development plans and provides improved chances for efficacy for individual patients.

Immunitas was founded to directly address the challenge of translating findings from laboratory research in model organisms to meaningful clinical advances in humans. Immunitas focuses on human samples, allowing the company to start with and stay closer to the most relevant and translatable biology for patients.

One of todays biggest challenges in oncology is how to efficiently and effectively move preclinical research into human therapies while avoiding the false signals often seen in animal models, said Dr. Jrgen Eckhardt, Head of Leaps by Bayer, Bayer AGs strategic venture capital unit. The scientific founders of Immunitas have elegantly solved this problem by dissecting the biology of immune cells in human tumors directly. We are excited to support this approach which has the potential to significantly improve cancer drug development.

Longwood-founded Immunitas also announced key senior management appointments as well as the Board of Directors of the company. Dr. Lea Hachigian is co-founder, director and President of Immunitas as well as a Principal at Longwood Fund. She is also a co-founder and director of TScan Therapeutics. Tarek Samad, Ph.D. is the Chief Scientific Officer at Immunitas Therapeutics. He has over two decades of experience in academia and industry leading small molecule and antibody biologic programs into the clinic. Amanda Wagner joins the company as Vice President of Strategy and Operations with over ten years of biotech experience in similar roles. The Board of Directors includes Dr. Laura Brass, Dr. Jrgen Eckhardt, Dr. Lea Hachigian, Dr. Lucio Iannone, Dr. Christoph Westphal, and Dr. Vincent Xiang.

About Immunitas Therapeutics

Immunitas Therapeutics, founded by Longwood Fund, employs a single cell genomics platform to dissect the biology of immune cells in human tumors, thereby advancing discoveries directly from the bench into meaningful clinical improvements. Our focus on human data allows us to start with and stay closer to the biology that is most relevant in patients and greatly accelerates the pace of our research. The Immunitas team of scientific pioneers innovates around each step of the drug development process, first identifying novel targets, then designing therapeutic strategies, and developing key biomarkers to guide the selection of patients who may benefit from our new drugs. http://www.ImmunitasTx.com.

Immunitas the human approach to oncology

The rest is here:
Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug...

Why I’m Holding On to My Bristol-Myers Squibb Shares Now That the Celgene Acquisition Has Closed – The Motley Fool

Goodbye, Celgene. Hello, Bristol-Myers Squibb (NYSE:BMY).

With Bristol-Myers Squibb's acquisition of Celgene closing on Wednesday, one of my favorite biotech stocks is now gone. Celgene became a subsidiary of BMS and is no longer a publicly traded company on its own. Like many former Celgene shareholders, I now own Bristol-Myers Squibb stock.

I've thought quite a bit about what I would do when the buyout deal concluded. My final conclusion: Do nothing. Here's why I plan to hold on to my new Bristol-Myers Squibb shares.

Image source: Getty Images.

I agree with market researcher EvaluatePharma that BMS's cancer immunotherapy Opdivo and its blood-thinning drug Eliquis are likely torank among the world's top-selling drugs over the next few years. But to be honest, the growth prospects for Opdivo and Eliquis alone wouldn't be enough to make me want to keep my newfound BMS shares. However, now that the big drugmaker owns Celgene's pipeline, it's a different story altogether.

Ozanimod appears to have very good chances of winning FDA approval for treating relapsed multiple sclerosis early next year. I expect the drug will generate peak annual sales in the ballpark of $5 billion if approved.

Celgene's cancer cell therapies liso-cel and ide-cel should also be in a pretty good position to secure regulatory approvals. These two drugs could tack on another $4 billion or so in combined peak annual sales. There could also be additional indications for recently approved Reblozyl (luspatercept) on the way that could help the drug achieve peak sales of close to $2 billion.

Looking farther down the road, I have high hopes for Celgene's CelMOD therapies that are currently in early stage clinical studies targeting blood cancers. I also think bb21217, a cell therapy that Celgene is developing with bluebird bio, could be a big winner.

These pipeline candidates make me excited about BMS's growth prospects. Yes, the company will have to offset the inevitable sales declines for Revlimid as generic rivals enter the market beginning in 2022. However, sales of those generics will be volume-limited at first. I think that the combination of Celgene's pipeline and already-approved drugs such as Pomalyst and Inrebic along with BMS's drugs should give the "new" company a solid growth runway.

In addition to its impressive blockbusters already mentioned, Bristol-Myers Squibb claims something remarkable of its own -- its dividend. The drugmaker's dividend currently yields 2.9%. That's a level that most investors would find quite attractive.

BMS has also been consistent at increasing its dividend payout through the years. Granted, those dividend hikes haven't been awe-inspiring. Still, a growing dividend is a good dividend in my book, especially with the already great yield.

I'm not worried at all about Bristol-Myers Squibb's ability to keep the dividends flowing and growing in the future. CFO Charles Bancroft noted in the company's third-quarter conference call that BMS will be able to increase its dividend, along with paying down its debt. He added that the company has "modeled annual increases" to its dividend in its pro forma financial projections.

It also helps that BMS just received $13.4 billion from the sale of Celgene's immunology drug Otezla to Amgen. While I would have preferred that BMS have Otezla in its lineup, the divestiture was necessary to make regulators happy and ended up being a good deal for all involved parties.

Celgene shareholders didn't just receive BMS stock with the closing of the acquisition. We also received $50 in cash per share plus a contingent value right (CVR) that will pay $9 if specified regulatory milestones are achieved.

I plan on holding on to my CVR. My expectation is that these CVR shares will eventually pay out the full $9 as BMS wins FDA approvals for ozanimod, liso-cel, and ide-cel.

As for the cash that I received with the acquisition of Celgene, I plan to invest in stocks, of course. Bristol-Myers Squibb won't be one of them, though, because I want to diversify more outside healthcare. The good news is that there are plenty of great stocks to choose from.

Go here to see the original:
Why I'm Holding On to My Bristol-Myers Squibb Shares Now That the Celgene Acquisition Has Closed - The Motley Fool

Road trip germs and how to avoid the grossness this holiday – CNN

(CNN) It's the time of year to pile the family into the car and make the trek to grandma's house.

No doubt you've got the packing down pat, as well as the best ways to entertain the kids as you travel. You've probably stashed some hand sanitizer for those thousands of restroom stops as well.

But have you thought of all of the other germs you might encounter on your journey?

Your car

Think of all the things you carry in your car -- and the germs that ride along. Not to mention the fact that most of us eat in our cars, scattering tasty bits to feed those microbes.

In fact, the study found the inside of the average car to be over 2,000 times germier than a phone, with more than 200 infectious bacteria per inch.

None of that surprises microbiologist Charles Gerba, a professor of public health, environmental science and immunology at the University of Arizona.

"I can actually tell by looking at the microbiology of a car where it is from in the US," Gerba said. Known as "Dr. Germ" for his abundant testing for germs on nearly every surface mankind might touch, Gerba's work is often commissioned by cleaning supply manufacturers to verify if their products work.

"We grew salmonella in the shop and we put them in the trucks of cars in different states," Gerba said. "In the south and Florida, it's nice and humid like a sauna so you get tons of bacteria. Michigan is like a refrigerator, so it's loaded with fungi because they grow better at the colder temperature."

However, in Arizona where Gerba lives, it's tougher for bacteria to survive: "They get toasted because it's 120 degrees in your trunk."

The solution is obvious: Clean the inside of your car with sanitizing wipes, change the air filters frequently to remove airborne particles, vacuum upholstery and sanitize floor mats. And don't forget to clean your keys.

Another germy surface you won't be able to avoid on your road trip: the gas station. The buttons you push to select and pay for gas harbor millions of bacteria, some dangerous, some not, according to the car rental survey. Gas pumps carried over 6,000 times the bacteria a public elevator button has and more than 11,000 times the germs of a public toilet seat.

Adding to my travel checklist: disposable plastic gloves.

Eating out on the road

Germs can spread through a family very quickly, as Gerba found out when he swabbed the hands of several families of four with a benign bacterium.

"Usually the germs spread to about 90% of the home's surfaces within four hours. I was actually kind of amazed," he said.

Just imagine what's happening in a restaurant that is serving one person (or family with small children in diapers) after another...

"Restaurant menus, they get pretty germy," Gerba said. "The plastic ones get really bad. Tabletops can be nasty too. We sampled tables at restaurants and asked the waiter or waitress to come over and wipe it clean."

Instead, Gerba said, "they usually put a thin layer of E. coli down on the table for us to eat off of."

"They're supposed to use disinfectants in these sponges and dish cloths, but apparently it's not effective enough," Gerba continued. "When they come to wipe my table off, I say 'Don't do it please. I'm fine.' "

Another note to self: Bring disinfectant wipes into restaurants every, single, time.

Self-checkouts

From the restaurant you just wiped down to the grocery store or quick mart you stopped at to get some snacks for the road, self-checkouts are another way to keep things moving quickly. Too bad they're so germy.

"We found a lot of fecal bacteria, antibiotic-resistant bacteria. I must say I was quite surprised," Gerba said. "They were worse than hospital screens that doctors and nurses touch. I certainly don't use the self-checkout anymore."

But here's some good news: When you pay for your items with cash, there's little chance of those dollar bills and coins passing on germs.

"We had people touch paper bills and very few bacteria, only 1%, came off," Gerba said.

"There may be bacteria but it doesn't transfer to your hands because bills tend to be porous. Coins tend to be somewhat anti-microbial; they are made of copper, silver and nickel. So, they didn't come out too bad in our studies either."

Too bad many of us don't carry much cash. Well, thank goodness for quick pay on our cell phones.

Oh, right. We carry those into the bathroom with us.

Hotel rooms

The nastiest item? The hotel TV remote.

Surprisingly, one of the least contaminated spots was the bathroom door handle.

Gerba tested hotel rooms that varied in price from $98 to $500 per night. You'd think the more expensive lodging would be less germy, but you'd be wrong. One 5-star hotel room had excessive levels of bacteria on the room service menu. Another disgusting item was the hotel hair dryer.

And when it comes to remote controls, Gerba's team found similar results as the Houston researchers, but with an extremely, uh, disturbing twist.

"Remote controls are the germiest thing in a hotel room," Gerba said. "In fact, we found semen on 30% of the remote controls we tested."

Speechless. But I can still scribble another note to myself: Next road trip bring enough plastic wrap to cover entire body.

Read more:
Road trip germs and how to avoid the grossness this holiday - CNN

Omeros’ New GPR174 Immuno-oncology Data Presented at the American Association for Cancer Research Conference In Boston Now Available Online – Business…

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented new GPR174 immuno-oncology data yesterday at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy in Boston, Massachusetts. The positively received and well-attended presentation about the companys cell-based and animal studies related to its newly discovered cancer immunity axis was made by Marc Gavin, Ph.D., Omeros Director of Immunology. This data can now be accessed on the companys website at https://investor.omeros.com/presentations

About Omeros Corporation

Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial product OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros has multiple Phase 3 and Phase 2 clinical-stage development programs focused on complement-mediated disorders and substance abuse, as well as a diverse group of preclinical programs including GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating platform.

Source: Omeros Corporation

Read the rest here:
Omeros' New GPR174 Immuno-oncology Data Presented at the American Association for Cancer Research Conference In Boston Now Available Online - Business...

Study involving U of T researchers suggests Ontario teen first case of ‘popcorn lung’ linked to vaping: CBC – News@UofT

An Ontario teen who was put on life support following a serious vaping-related illness may be the first known case of a form of lung damage caused by vaping, according to a study co-authored by Tereza Martinu and Andrew Steel of the University of Torontos Faculty of Medicine.

Martinu, an assistant professor in thedepartment of immunology who was part of the team of doctors who cared for the 17-year-old at Toronto General Hospital, told CBC News that the teen appeared to suffer from bronchiolitis obliterans or popcorn lung, rather than the illness dubbed EVALI (e-cigarette or vaping product use-associated lung injury).

"It was a relatively wild story; we have not seen something like this that often," said Martinu, a lung transplant respirologist who co-authored the study published in the Canadian Medical Association Journal. "The referring team was really worried that he was not going to make it."

The teens condition eventually improved after treatment with steroids, with Martinu saying he may have suffered chronic lung damage.

"If he truly does have this bronchiolitis oblitirans scarring problem that we're worried about, he will likely remain with some amount of lung disease," she said. "But we won't really know until we see how it evolves."

Read the original:
Study involving U of T researchers suggests Ontario teen first case of 'popcorn lung' linked to vaping: CBC - News@UofT

Lung response to bacteria revealed by researchers – Drug Target Review

A study has discovered the process behind the lung immune response, which could be used to develop treatments against pneumonia.

Researchers have revealed the process that the lungs use in the body to defend themselves against bacteria. According to the team, their findings could be used to develop treatments against pneumonia.

The study was conducted at Boston University School of Medicine (BUSM), US.

The study was designed to generate knowledge about the immune components that are useful for fighting pneumonia

Previous research has demonstrated that recovery from bacterial pneumonia improves the bodys defence against further infections through lung resident memory T (TRM) cells. However, the way in which these cells protect the lungs has been unknown until now.

The team found that TRM cells surrounding lung cells send out a signal to recruit bacteria killers called neutrophils.

Using experimental models, the researchers developed ways to deplete TRM cells to determine how they affected the lungs response to infection.

Because we found that the lung-lining cells changed their behaviour when TRM cells were missing, we studied those lung-lining cells in culture, including how they responded to TRM-derived signals to generate neutrophil-recruiting signals, explained corresponding author Professor Joseph Mizgerd.

According to the researchers, the study was designed to generate knowledge about the immune components that are useful for fighting pneumonia. Over the long-term, our study has implications for preventing and treating pneumonia which is important for keeping people out of the hospital and for preventing hospitalised patients from progressing to the intensive care unit and even worse outcomes, said Mizgerd.

Mizgerd envisions a future in which clinicians can measure and report a persons lung immunity and pneumonia susceptibility status: Interventions could be developed to improve an individuals lung immunity in order to prevent pneumonia and lung immunity is manipulated, triggered or mimicked in pneumonia patients to accomplish a cure against drug-resistant organisms or microbes for which no drugs have yet been developed.

The study was published in Mucosal Immunology.

Read more:
Lung response to bacteria revealed by researchers - Drug Target Review

Diversity Marks Latest Class of US Rhodes Scholars – The New York Times

Minorities make up the majority of the latest group of U.S. college students to be named Rhodes Scholars, and the class includes the first transgender woman selected for the prestigious program.

The Rhodes Trust announced the 32 selections late Saturday after two days of discussions over 236 applicants from 90 different colleges and universities across the country.

Along with University of Tennessee graduate Hera Jay Brown, who is the first transgender woman in the program, this years class also includes two non-binary scholars.

As our rights and experiences as women are under threat, this moment has given me pause to reflect on what an honor it is to pave this path, Brown posted on Twitter after the announcement.

There are students from universities well known for their academics, such as the Massachusetts Institute of Technology, Harvard University and Duke University. The list also includes the first Rhodes Scholar from the University of Connecticut.

The 32 people chosen will start at least two years of all-expenses paid study next fall at Oxford University in England along with students from over 60 countries.

The studies undertaken by the scholars include research into the escape from danger reflex in zebrafish to better understand how the human brain deals with stress and how to make computer vision more humanlike.

The research also includes studies into human behavior, including the prevalence of sex work among refugees, the impact of nuclear testing on the American Southwest, how to use online cryptocurrency to improve conditions in the worlds largest Syrian refugee camp and defending the rights of migrants to the United States.

Winners of the scholarships include Daine A. Van de Wall, who is a brigade commander at the United States Military Academy, which is the highest-ranking cadet position at West Point.

Other scholars selected this year include students who were homeschooled before their university studies and some who are the first people in their families to go to college.

Arielle Hudson is a second-generation student at the University of Mississippi who remembered visiting campus with her mother, who holds two degrees from the school. She always thought she would go to college out of state until she received a full scholarship through a Mississippi teaching program.

When I received the scholarship, I started to think about how I would make a difference here, Hudson told the university in a statement.

Now her work will come full circle. Hudson plans to seek masters degrees in comparative social policy and comparative international education, then come back to Mississippis poor Delta region to teach for five years to fulfill her scholarship requirement.

Rhodes Scholarships were created in 1902 in the will of Cecil Rhodes, a British businessman and Oxford alum who was a prime minister of the Cape Colony in present-day South Africa.

The recipients are chosen not just for academic skill, but for their leadership and a willingness to do good for the world.

Previous Rhodes Scholars include U.S. President Bill Clinton, astronomer Edwin Hubble, singer-songwriter Kris Kristofferson and author Naomi Wolf. Among 2020 Democrats running for president, Cory Booker and Pete Buttigieg both studied at Oxford under the scholarship program.

More:
Diversity Marks Latest Class of US Rhodes Scholars - The New York Times

The First Step Act promised widespread reform. What has the criminal justice overhaul achieved so far? – NBC News

In 2004, when Tanesha Bannister was 29, a judge sentenced her to life in prison for selling crack, convincing the single mother of two she'd never be free again.

Two decades earlier, the country had responded to the crack cocaine epidemic with laws that hoped to stem both violence and social decay caused by low-cost crack cocaine. Over time, the 1986 law mandating a 100-to-1 crack versus powder cocaine sentencing ratio marooned millions of Americans, mostly black men, in Americas prison system.

But as her time in prison stretched on, Bannister, who is black, began to question the legitimacy of her punishment for a non-violent crime. She petitioned the administrations of President Barack Obama and President Donald Trump for a reprieve to no avail.

Then, in May, she became one of the more than 4,500 people released or who have seen their prison terms shortened since December 2018, when Trump signed into law one of the most significant changes to the federal criminal justice system in the 21st century.

"Basically after being let down for so many times ... it was just like life was breathed all over again," Bannister, now 45, said.

Nearly a year after the First Step Act's passage, NBC News spoke to over a dozen people, including former and current elected officials, liberal and conservative advocates, and formerly incarcerated individuals, among others, who championed the reforms. They all agreed that the law's effects are tangible, and many believe the bipartisan coalition that produced it appears durable.

I think the biggest win is that this is now a safe issue after years and years and years of the two parties trying to use criminal justice as a way to tear each other down, said Jessica Jackson, co-founder of #cut50, a bipartisan criminal justice reform nonprofit.

However, some are skeptical the alliance can hold. Many of the next steps advocates have underscored as necessary to bring about true change, like reexamining lengthy sentences for violent offenses and restructuring policing practices, may be a tougher sell.

"As some people might say, it's easier to kind of agree on some of the low-hanging fruits, but the higher you reach, the more difficult consensus is going to be, said Tim Head, the executive director for the Faith & Freedom Coalition, a conservative nonprofit that supports the act as well as other criminal justice reform efforts.

More than 3,000 inmates have been released and another roughly 1,700 people convicted of crack cocaine offenses have seen their sentences reduced thanks to the First Step Act, according to data from the Federal Bureau of Prisons and the U.S. Sentencing Commission. Some of that activity stems from a 2011 change made by the federal sentencing commission affecting people convicted of certain drug crimes and a provision of the First Step Act. That provision made the sentencing guidelines of the Obama-era Fair Sentencing Act of 2010 retroactive.

The majority of those released under both acts have been black men, the group which the "war on drugs" campaign of the '70s and '80s effectively targeted.

But the effects of the act's other major provision the relaxing of the notorious "three strikes" rule to mean a 25-year sentence, rather than life in prison, for three or more convictions are so far difficult to measure. A year in, little data has been collected around how many people had been sentenced under the new guidelines.

Let our news meet your inbox. The news and stories that matters, delivered weekday mornings.

The act also a required the development of a new risk assessment tool that aims to determine which inmates are most likely to re-offend if released and to identify ways to assist those who are released. It was completed in July. Meanwhile, roughly 16,000 federal prisoners have enrolled in drug treatment programs created by the act, according to the Justice Department.

The success or limitations of the tool and the new programs still remain to be seen, but advocates say the overall represent a major shift in thinking.

"It's part of wider system transformation from one that was based on gut instinct and anecdotes and headlines to decisions that are made based on evidence and research," said Adam Gelb, the founder of the Council on Criminal Justice, a bipartisan criminal justice nonprofit.

However, he added, the nuances of implementation matter.

"We're talking about human behavior and it's never going to be a perfect assessment of someone's readiness for release nor a perfect judgment about the length of time they deserve to spend behind bars for the purposes punishment," he said.

Head, the executive director of the Faith and Freedom Coalition, said the act's changes, which also include mandating BOP train its 31,000 employees on de-escalation techniques and mental health awareness, intended to shift "the culture of our federal system from pure punishment, to one of at least considering rehabilitation in a much more meaningful way."

The idea of rehabilitation and redemption, he said, is a core focus of conservative thought on the issue.

But, despite the sweeping reforms of the First Step Act, other experts say it's important not lose sight of the inmates who have been left out of the reforms and to start a conversion about about whether prison is the right punishment in a country that incarcerates more people than its peers.

"We have so much work to do to re-imagine our system of corrections, our system of justice, so we just need to be careful not to paint sort of a rosy picture of what's happening," Lauren-Brooke Eisen, an expert at the Brennan Center. "We still have more people behind bars under correctional supervision than any other country on the planet."

Advocates for the First Step Act, particularly left-leaning ones, describedits reformsashistoric but modest. True change will require looking to the heart of the system police interactions and what happens inside courtrooms, experts said. Right now, black Americans are more likely to be arrested for the same activities as white Americans, and more likely to be prosecuted, convicted and sentenced to longer jail terms.

It's understandable that people are frustrated with the pace of progress, said Gelb. At the same time, the criminal justice system is massive and fragmented. And it's going to continue to take some time to build the political will to tackle many of the more difficult issues.

Gil Kerlikowske, the former commissioner of U.S. Customs and Border Protection and drug czar under President Barack Obama, suggested that reformers look to the states. First Step covers the nearly 180,000 federal inmate population, and does not touch the roughly 1.3 million people in state prisons.

"I think that the states have been moving in this direction now for quite a while, he said. But I think the First Step Act sends a good signal nationally, because not all states are on board, and not all states move as aggressively."

To make a more significant dent in the nations prison population, attention must shift toward the roots of mass incarceration, said Tony J. Payton Jr., a Democrat and former Pennsylvania state lawmaker who championed state-level criminal justice reforms.

Weve got to basically dismantle that entire system, said Payton, who is now affiliated with the 20/20 Bipartisan Justice Center, a national and bipartisan coalition of black criminal justice reformers.

Payton's list of targets, however, points to some of the remaining contentious matters in criminal justice reform that could threaten the bipartisanship needed to implement them, such as sentencing reform for both non-violent and violent offenders, eliminating mandatory minimums, reforming police departments and eliminating prosecutorial immunity.

Lester Young Jr., a South Carolina statewide organizer for JustLeadershipUSA, a national criminal justice reform nonprofit, who was formerly incarcerated for murder, cited his own experience to argue that reforms for violent offenders must be made a priority.

Head said that this might make some conservatives uneasy.

"On the conservative side of the spectrum, there obviously still are plenty of people that feel like the most severe crimes or severe offenses need to be dealt with severely," Head said. "People on the right saying, 'This goes too far' and people on the left saying, 'This doesn't go far enough.'"

Bannister, released from the minimum-security penitentiary in Bryan, Texas, where she spent 16 years, now works as a personal care assistant for two health care companies back home in South Carolina.

She's turned her efforts to activism after being released, hoping to lobby state lawmakers to improve reentry for ex-offenders with resources such as housing and job training.

"There's a lot of work to do, but I'm willing to stand in the trenches and fight the good fight and if I can make a difference in getting a law passed or writing legislation, those are my goals," she said. "They're not things I want to fulfill but I will fulfill."

Read this article:
The First Step Act promised widespread reform. What has the criminal justice overhaul achieved so far? - NBC News

Inside the Archive of an LSD Researcher With Ties to the CIA’s MKUltra Mind Control Project – The Intercept

On the night of July 4, 1954, San Antonio, Texas, was shaken by the rape and murder of a 3-year-old girl. The man accused of these crimes was Jimmy Shaver, an airman at the nearby Lackland Air Force Base with no criminal record. Shaver claimed to have lost his memory of the incident.

The victim, 3-year-old Chere Jo Horton, had disappeared around midnight outside the Air Force Base, where her parents had left her in the parking lot outside a bar; she played with her brother while they had a drink inside. When they noticed her missing, they formed a search party.

Within an hour, the group came upon a car parked next to a gravel pit; Cheres underwear was hanging from one of the cars doors. Shaver wandered out of the darkness. He was shirtless, covered in blood and scratches. Making no attempt to escape, he let the search party walk him to the edge of the highway. Bystanders described him as dazed and in a trance-like state.

Whats going on here? he asked. He didnt seem drunk, but he couldnt say where he was, howd he gotten there, or whose blood was all over him. Meanwhile, the search party found Hortons body in the gravel pit. Her neck was broken, her legs had been torn open, and shed been raped.

Deputies arrested Shaver. At 29, he was recently remarried with two children and no history of violence. Hed been at the same bar Horton had been abducted from, but hed left with a friend, who told police that neither of them was drunk, though Shaver had seemed high on something. Before deputies could take Shaver to the county jail, a constable from another precinct arrived with orders from military police to assume custody of him.

Around four that morning, an air force marshal questioned Shaver and two doctors examined him, agreeing he wasnt drunk. One later testified that he probably was not normal he was very composed outside, which I did not expect him to be under these circumstances. He was released to the county jail and booked for rape and murder.

Investigators interrogated Shaver through the morning. When his wife came to visit, he didnt recognize her. He gave his first statement at 10:30 a.m., adamant that another man was responsible: He could summon an image of a stranger with blond hair and tattoos. After the air force marshal returned to the jailhouse, however, Shaver signed a second statement taking full responsibility. Though he still didnt remember anything, he reasoned, he must have done it.

Two months later, in September, Shavers memories still hadnt returned. The commander of the base hospital, Col. Robert S. Bray, ordered a psychiatric evaluation, to be performed by Dr. Louis Jolyon West, the head of psychiatric services at the air base. It fell to West to decide if Shaverhad been legally sane at the time of the murder.

Shaver spent the next two weeks under Wests supervision. They returned to the scene of the crime, trying to jog his memory. Later, West hypnotized Shaver and gave him an injection of sodium pentothal, or truth serum, to see if he could clear his amnesia.

While Shaver was under, according to testimony, he recalled the events of that night. He confessed to killing Horton. Shed brought out repressed memories of his cousin, Beth Rainboat, whod sexually abused him as a child. Shaver had started drinking at home that night when he had visions of God, who whispered into his ear to seek out and kill the evil girl Beth.

While Shaver was under hypnosis, he confessed to killing the young girl. At trial, he maintained his innocence.

At the trial, West made only a minimal effort to exonerate Shaver. The airman was found guilty. Though an appeals court later ruled that hed had an unfair trial, he was convicted again in the retrial. In 1958, on his33rd birthday, he was executed by the electric chair. He maintained his innocence the whole time.

The trial, which hinged on Shavers testimony, might have ended differently had the jury knownabout Wests past. According to newly surfaced papers fromWests archives,the psychiatrist had some of the clearest, most nefarious ties of any scientist to the CIAs Project MKUltra. Wests files especially his correspondence with the CIAs longtime poisons expert, Sidney Gottlieb shed new light on one of the most infamous projects in the agencys history. Likely comprising more than149 subprojects and at least 185 researchers working at institutions across America and Canada, MKUltra was, as the New York Times put it, a secret twenty-five year, twenty-five million dollar effort by the CIA to learn how to control the human mind. Its experiments violated international laws, not to mention the agencys charter, which forbids domestic activity.

At the trial, West maintained that Shaver had suffered a bout of temporary insanity on the night of Chere Jo Hortons killing, but he argued that Shaver was quite sane now. In the courtroom, Shaver didnt look that way. One newspaper account said he sat through the strenuous sessions like a man in a trance, saying nothing, never rising to stretch or smoke, though he was a known chain-smoker.

Large portions of Wests truth serum interview with Shaver were read into the court record. The doctor had used leading questions to walk the entranced Shaver through the crime. Tell me about when you took your clothes off, Jimmy, hed said. The transcript of the interview, which survived among Wests papers, also showed West trying to prove that Shaver had repressed memories: Jimmy, do you remember when something like this happened before? Or: After you took her clothes off, what did you do?

I never did take her clothes off, Shaver said.

The interview was divided into thirds, and the middle third hadnt been recorded. When the transcript picked up, it said: Shaver is crying. He has been confronted with all the facts repeatedly.

West asked, Now you remember it all, dont you, Jimmy?

Yes, sir, Shaver replied.

Though lawyers scrutinized Shavers medical history, little mention was made of the base hospital where Wests archived letters indicate he had conducted his MKUltra experiments. Shaver had suffered from migraines so debilitating that hed dunk his head in a bucket of ice water when he felt one coming on. His condition was severe enough that the Air Force had recommended him for a two-year experimental program. The doctor whod attempted to recruit him wasnot named in court records or transcripts.

On the stand, West said hed never gotten around to seeing whether Shaver had been treated in the experimental program. Lackland officials told me there was no record of him in their master index of patients. But, curiously, according to the bases archivist, all the records for patients in 1954 had been maintained, with one exception: the file for last names beginning with Sa through St had vanished.

Dr. Louis Jolyon West in San Francisco, Calif., in 1976.

Photo: Lawrence Schiller/Polaris Communications/Getty Images

Wests professional fascination with LSD was practically as old as the drug itself. For several decades, he was one of an elite cadre of scientists using it in top-secret research. Lysergic acid diethylamide was synthesized in 1938 by chemists at Switzerlands Sandoz Industries, but it was not introduced as a pharmaceutical until 1947. In the fifties, when the CIA began to experiment on humans with it, it was a new substance. Albert Hofmann, the Swiss scientist whod discovered its hallucinogenic qualities in 1943, described it as a sacred drug that gestured toward the mystical experience of a deeper, comprehensive reality.

In the 50s, even before hippies embraced the drug, Very few people took LSD without having somebody being a trip leader, Charles Fischer, a drug researcher, told me. The suggestibility from LSD was akin to that associated with hypnosis; West had studied the two in tandem. You can tell somebody to hurt somebody, but you call it something else, Fischer explained. Hammer the nail into the wood, and the wood, perhaps, is a human being.

West seems to have used chemicals liberally in his medical practice, and histacticsleft an indelible mark on the psychiatrists who worked with him. One of them, Gilbert Rose, was so baffled by the Shaver case that he went on to write a play about it.

In my 50 years in the profession, that was the most dramatic moment ever when he clapped his hands to his face and remembered killing the girl, Rose said in 2002 of Shaver and the truth serum interview. But Rose was shocked when I told him that West had hypnotized Shaver in addition to giving him sodium pentothal. Hypnotism, he said, was not part of the protocol for the interview.

Hed also never known how West had found out about the case right away.

We were involved from the first day, Rose recalled. Jolly phoned me the morning of the murder. He initiated it.

West claimed he was in the courtroom the day Shaver was sentenced to death. Around this time, he became vehemently opposed to capital punishment. Did he know his experiments mightve led to the execution of an innocent man and the death of a child? If his correspondence with CIA head of MKUltra Gottlieb predating the crime by just a year had been presented at trial, would the outcome have been the same?

Almost as soon as they had access to it, government scientists saw LSD as a potential Cold War miracle drug. Full-fledged U.S. research into LSD began soon after the end of World War II, when American intelligence learned that the USSR was developing a program to influence human behavior through drugs and hypnosis. The United States believed that Soviets could extract information from people without their knowledge, program them to make false confessions, and perhaps persuade them to kill on command.

In 1949, the CIA, then in its infancy, launched Project Bluebird, a mind-control program that tested drugs on American citizens most in federal penitentiaries or on military bases who didnt even know about, let alone consent to, the battery of procedures they underwent.

Their abuse found further justification in 1952, when, in Korea, captured American pilots admitted on national radio that theyd sprayed the Korean countryside with illegal biological weapons. It was a confession so beyond the pale that the CIA blamed communists: The POWs must have been brainwashed. The word, a literal translation of the Chinese xi nao, didnt appear in English before 1950. It articulated a set of fears that had coalesced in postwar America: that a new class of chemicals could rewire and automate the human mind.

You can tell somebody to hurt somebody, but you call it something else, Fischer explained. Hammer the nail into the wood, and the wood, perhaps, is a human being.

When the American POWs returned, the Army brought in a team of scientists to deprogram them. Among those scientists was West. Born in Brooklyn in 1924, he had enlisted in the Air Force during World War II, eventually rising to the rank of colonel. His friends called him Jolly, for his middle name, impressive girth, and oversized personality. When he got out, he researched methods of controlling human behavior at Cornell University. He would later claim to have studied 83 prisoners of war, 56 of whom had been forced to make false confessions. He and his colleagues were credited with reintegrating the POWs into Western society and, maybe more important, getting them to renounce their claims about having used biological weapons.

Wests success with the POWs gained him entrance into the upper echelons of the intelligence community. Gottlieb,the poisons expert who headed the chemical division of the CIAs Technical Services Staff, along with Richard Helms, the CIAs chief of operations for the Directorate of Plans had convinced the agencys then-director, Allen Dulles, that mind control ops were the future. Initially, the agency wanted only to prevent further potential brainwashing by the Soviets. But the defensive program became an offensive one. Operation Bluebird morphed into Operation Artichoke, a search for an all-purpose truth serum.

In a speech at Princeton University, Dulles warned that communist spies could turn the American mind into a phonograph playing a disc put on its spindle by an outside genius. Just days after those remarks, on April 13, 1953, he officially set Project MKUltra in motion.

Little is known about the program. After Watergate, Helms (who by that time was CIA director) ordered Gottlieb to destroy all MKUltra papers; in January 1973, the Technical Services staff shredded countless documents describing the use of hallucinogens.

In the mid-1970s, after the Times revealed the existence of MKUltra on its front page, the government launched three separate investigations, all of which were hobbled by the CIAs destruction of its files:Vice President Nelson Rockefellers Commission on CIA Activities within the United States (1975); Senator Frank Churchs Senate Select Committee to Study Governmental Operations with Respect to Intelligence Activities (1975-6); and Senators Edward Kennedy and Daniel Inouyes joint Senate Select Committee hearings on Project MKUltra, the CIAs Program of Research in Behavioral Modification (1977). When records were available, they were redacted; when witnesses were summoned to testify before Congress, they were forgetful.

We do know the projects broadest goal was to influence human behavior. Under its umbrella were at least 149 subprojects, many involving research on unwitting participants. Gottlieb, whose aptitude and amorality earned him the nickname the Black Sorcerer, developed gadgetry straight out of schlocky sci-fi: high-potency stink bombs, swizzle sticks laced with drugs, exploding seashells, poisoned toothpaste. Having persuaded an Indianapolis pharmaceutical company to replicate the Swiss formula for LSD, the CIA had a limitless domestic supply of its favorite new drug. The agency hoped to produce couriers who could embed hidden messages in their brains, to implant false memories and remove true ones in people without their awareness, to convert groups to opposing ideologies, and more. The loftiest objective was the creation of hypno-programmed assassins.

The most sensitive work was conducted far from Langley farmed out to scientists at colleges, hospitals, prisons, and military bases all over the United States and Canada. The CIA gave these scientists aliases, funneled money to them, and instructed them on how to conceal their research from prying eyes, including those of their unknowing subjects.

Their work encompassed everything from electronic brain stimulation to sensory deprivation to induced pain and psychosis. They sought ways to cause heart attacks, severe twitching, and intense cluster headaches. If drugs didnt do the trick, theyd try to master ESP, ultrasonic vibrations, and radiation poisoning. One project tried to harness the power of magnetic fields.

MKUltra was so highly classified that when John McCone succeeded Dulles as CIA director late in 1961, he was not informed of its existence until 1963. Fewer than half a dozen agency brass were aware of it at any period during its 20-year history.

Sidney Gottlieb in 1977.

Photo: AP

West headed the psychiatry department at UCLA and the schools renowned neuroscience center until his retirement in 1988. One day, among a batch of research papers on hypnosis in Wests archives there, I found letters between West and his CIA handler, Sherman Grifford the cover name, according to John Markss The Search for the Manchurian Candidate, for Sidney Gottlieb. West, who had once written to a magazine editor that he had never worked for the CIA, had in fact worked closely with the agencys Black Sorcerer himself.

The letters picked up midstream, with no prologue or preliminaries. The first was dated June 11, 1953, a mere two months after MKUltra started, when West was chief of the psychiatric service at the air base at Lackland.

Who would the guinea pigs be?West listed four groups: basic airmen, volunteers, patients, and others, possibly including prisoners in the local stockade.

Addressing Gottlieb as S.G., West outlined the experiments he proposed to perform using a combination of psychotropic drugs and hypnosis. He began with a plan to discover the degree to which information can be extracted from presumably unwilling subjects (through hypnosis alone or in combination with certain drugs), possibly with subsequent amnesia for the interrogation and/or alteration of the subjects recollection of the information he formerly knew. Another item proposed honing techniques for implanting false information into particular subjects or for inducing in them specific mental disorders. He hoped to create couriers who would carry a long and complex message embedded secretly in their minds, and to study the induction of trance-states by drugs. His list lined up perfectly with the goals of MKUltra.

Needless to say, West added, the experiments must eventually be put to test in practical trials in the field. To this end, he asked Gottlieb for some sort of carte blanche.

Who would the guinea pigs be? He listed four groups: basic airmen, volunteers, patients, and others, possibly including prisoners in the local stockade. Only the volunteers would be paid. The others could be unwilling, and, though it wasnt spelled out, unwitting. It would be easier to preserve his secrecy if he were inducing specific mental disorders in people who already exhibited them. Certain patients requiring hypnosis in therapy, or suffering from dissociative disorders (trances, fugues, amnesias, etc.) might lend themselves to our experiments. Official investigations into MKUltra yielded little information about its subjects, but Wests letter suggests that the program cast a wide net.

Gottliebs reply came on letterhead from Chemrophyl Associates, a front company he used to correspond with MKUltra subcontractors. My Good Friend, he wrote, I had been wondering whether your apparent rapid and comprehensive grasp of our problems could possibly be real. you have indeed developed an admirably accurate picture of exactly what we are after. For this I am deeply grateful.

Gottlieb saluted his new recruit: We have gained quite an asset in the relationship we are developing with you.

West returned the camaraderie: It makes me very happy to realize that you consider me an asset, he replied. Surely there is no more vital undertaking conceivable in these times.

In 1954, around the same time as Chere Jo Hortons murder, West began to split his time between Lackland and the University of Oklahoma School of Medicine, where he would lead the psychiatry department.

West had told his prospective employer that his Lackland duties were purely clinical and that hed been doing no research, classified or otherwise and he asked the board of directors at Oklahoma for permission to accept money from the Geschickter Fund for Medical Research, which he called a non-profit private research foundation. In fact, as the CIA later acknowledged, Geschickter was another of Gottliebs fictions, a shell organization enabling him.

In 1956, West reported back to the CIA that the experiments hed begun in 1953 had at last come to fruition. In a 1956 paper titled The Psychophysiological Studies of Hypnosis and Suggestibility, he claimed to have achieved the impossible: He knew how to replace true memories with false ones in human beings without their knowledge. Without detailing specific incidents, he put it in laymans terms: It has been found to be feasible to take the memory of a definite event in the life of an individual and, through hypnotic suggestion, bring about the subsequent conscious recall to the effect that this event never actually took place, but that a different (fictional) event actually did occur. Hed done it, he claimed, by administering new drugs effective in speeding the induction of the hypnotic state and in deepening the trance that can be produced in given subjects.

At the National Security Archives in D.C., I found the version of The Psychophysiological Studies of Hypnosis and Suggestibility that the CIA turned over to Senators Kennedy and Inouyein 1977. Wests name and affiliation were redacted, as expected. But the CIAs version was also shorter, and watered down in comparison. Wests document was 14 pages. This one was five, including a cover page. Most glaringly, there was no mention of Wests triumphant accomplishment, the replacement of the memory of a definite event in the life of an individual with a fictional event.

One passage, not in Wests original, claims the CIA never used LSD in studies at all: The effects of [LSD and other drugs] upon the production, maintenance, and manifestations of disassociated states has never been studied.

West, of course, had studied those effects for years. But when it came to elaborating on his findings about implanting memories and controlling thoughts, even in the paper found in Wests own files, he offered few details. He seems to have been in a rudimentary phase of his research. Acid, he wrote, made people more difficult to hypnotize; it was better to pair hypnosis with long bouts of isolation and sleep deprivation. Using hypnotic suggestion, he claimed, a person can be told that it is now a year later and during the course of this year many changes have taken placeso that it is now acceptable for him to discuss matters that he previously felt he should not discussAn individual who insists he desires to do one thing will reveal that secretly he wishes just the opposite.

Had the CIA doctored Wests original document to mislead the Senate committee? And if so, why would the agency have gone to so much trouble to hide experimental findings that werent ultimately all that revealing? Agency officials claimed the program had been a colossal failure, leading to mocking headlines like the The Gang That Couldnt Spray Straight. Perhaps the agency wanted the world to assume that MKUltra was a bust, and to forget the whole thing.

The official seal of the CIA in 1974.

Photo: Bettmann Archive/Getty Images

The CIA seemsto have pared MKUltra back in the mid-60s, according to congressional testimony and surviving financial records, but Jolly Wests government-funded research continued apace. Late in the fall of 1966, West arrived in San Francisco to study hippies and LSD. Tall, broad, and crew cut, with an all-American look in keeping with his military past, he cobbled together a new wardrobe and started skipping haircuts. He secured a government grant and took a yearlong sabbatical from the University of Oklahoma, nominally to pursue a fellowship at Stanford, although that school had no record of his participation in a program there.

When he arrived in Haight-Ashbury, West was the only scientist in the world whod predicted the emergence of potentially violent LSD cults such as Charles Mansons Family. In a 1967 psychiatry textbook, West had contributed a chapter called Hallucinogens, warning students of a remarkable substance percolating through college campuses and into cities. LSD was known to leave users unusually susceptible and emotionally labile. It appealed to alienated kids who would crave shared forbidden activity in a group setting to provide a sense of belonging.

Acid, he wrote, made people more difficult to hypnotize; it was better to pair hypnosis with long bouts of isolation and sleep deprivation.

Another of his papers, 1965s Dangers of Hypnosis, foresaw the rise of dangerous groups led by crackpots who hypnotized their followers into violent criminality. He cited two cases: a double murder in Copenhagen committed by a hypno-programmed man, and a military offense induced experimentally at an undisclosed U.S. Army base. (Its not at all clear that the latter referred to Shavers killing of Chere Jo Horton.)

Hed also supervised a study in Oklahoma City,in which hed hired informants to infiltrate teenage gangs and engender a fundamental change in basic moral, religious or political matters. The title of the project was Mass Conversion, and ithad been funded by Gottlieb.

In the Haight, West arranged for the use of a crumbling Victorian house on Frederick Street, where heset up what he described as a laboratory disguised as a hippie crash pad. The pad opened in June 1967, at the dawn of the summer of love. He installed six graduate students in the pad, telling them to dress like hippies and lure itinerant kids into the apartment. Passersby were welcome to do as they pleased and stay as long as they liked, as long as they didnt mind grad students taking notes on their behavior.

According to records in Wests files, his crash pad was funded by the Foundations Fund for Research in Psychiatry, Inc., which had bankrolled a number of his other projects, too, across decades and institutions. Dr. Gordon Deckert, Wests successor as chair at the University of Oklahoma, told me that he found papers in Westsdesk that revealed that the Foundations Fund was a front for the CIA.

This wouldnt have been the agencys first disguised laboratory in San Francisco. A few years earlier, the evocatively titled Operation Midnight Climax had seen CIA operatives open at least three Bay Area safe houses disguised as upscale bordellos, kitted out with one-way mirrors and kinky photographs. A spy named George Hunter White and his colleagues hired prostitutes to entice prospective johns to the homes, where the men were served cocktails laced with acid. The goal was to see if LSD, paired with sex, could be used to coax sensitive information from the men. White later wrote to his CIA handler, I was a very minor missionary, actually a heretic, but I toiled wholeheartedly in the vineyards because it was fun, fun, fun.

At the Haight-Ashbury pad, though, Wests motives were vague. No oneseemed to havea firm grasp of the projects purpose not even those involved in it. The grad students hired tostaffWests crash pad lab were assigned to keep diaries of their work. In unguarded moments, nearly all of these students admitted that something didnt add up. They werent sure what they were supposed to be doing, or why West was there. And often he wasnt there.

One of the diaries in Wests files belonged to a Stanford psychology grad student who lived at the pad that summer. The experience was aimless to the point of worthlessness, she wrote. When crashers showed up, no one made much of a point of finding out about [them]. More often, hippies failed to show up at all, since many of them apparently looked on the pad with suspicion. What the hell is Jolly doing, it is like a zoo, the student fumed. Is he studying us or them?

When West made one of his rare appearances, he was dressed like a silly hippie; sometimes he brought friends to the house. Their general attitude,she wrote, was that this was a good opportunity to have fun. They spent a good deal of the time stoned. She added, I feel like no one is being honest and straight and the whole thing is a gigantic put on. What is he trying to prove? He is interested in drugs, that is clear. What else?

In December 1974, MKUltra finally came to light in a terrific flash of headlines and intrigue. Seymour Hersh reported it on the front page of the Times: Huge C.I.A. Operation Reported in U.S. Against Antiwar Forces. The three government investigations that followed the Rockefeller Commission, Church Committee, and the Kennedy-Inouye Select Committee hearings looked into illegal domestic activities of various federal intelligence agencies, including wiretapping, mail opening, and unwitting drug testing of U.S. citizens.

TheChurch Committeesfinal report unveiled a 1957 internal evaluation of MKUltra by the CIAs inspector general. Precautions must be taken, the document warned, to conceal these activities from the American public in general. The knowledge that the agency is engaging in unethical and illicit activities would have serious repercussions. A 1963 review from the inspector general put it even more gravely: A final phase of the testing of MKUltra products places the rights and interests of U.S. citizens in jeopardy.

The Church Committee found that MKUltra had caused the deaths of at least two American citizens. One was a psychiatric patient whod been injected with a synthetic mescaline derivative. The other was Frank Olson, a military-contracted scientist whod been unwittingly dosed with LSD at a small agency gathering in the backwoods of Maryland presided over by Gottlieb himself. Olson fell into an irreparable depression afterward, which led him to hurl himself out the window of a New York City hotel where agents had brought him for treatment. (Continued investigation by Olsons son, Eric dramatized by Errol Morris in the series Wormwood strongly suggests that the CIA arranged for the agents to fake his suicide,throwing him out of the windowbecause they fearedhe would blow the whistle on MKUltra and the militarys use of biological weapons in the Korean War.)

The Statler Hotel in New York, N.Y. where Frank Olson fell to his death.

Photo: Bettmann Archive/Getty Images

The news of Olsons death shocked a nation already reeling from Watergate, and now less inclined than ever to trust its institutions. The government tried to quell the controversy by passing new regulations on human experimentation. Gottliebs destruction of the MKUltra files was investigated by the Justice Department in 1976, but, according to the Times, quietly dropped. Gottlieb had testified before the Senate in 1977 only under the condition that he received criminal immunity.

The Senate demanded the formation of a federal program to locate the victims of MKUltra experiments, and to pursue criminal charges against the perpetrators. That program never coalesced. Surviving records named 80 institutions, including 44 universities and colleges, and 185 researchers, among them Louis Jolyon West. The Times identifiedWest as one of less than a dozen suspected scientists whod secretly participated in MKUltra under academic cover.

Yet not one researcher was ever federally investigated, nor were any victims ever notified. Despite the outrage of congressional leaders and more than three years of headlines about the brutalities of the program, no one not the Black Sorcerer Sidney Gottlieb, nor senior CIA official Richard Helms, nor Jolly West suffered any legal consequences.

See the original post here:
Inside the Archive of an LSD Researcher With Ties to the CIA's MKUltra Mind Control Project - The Intercept